Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ADC Therapeutics (ADCT – Research Report), Adial Pharmaceuticals (ADIL – Research Report) and Steris (STE – Research Report).
ADC Therapeutics (ADCT)
Capital One Financial analyst Naureen Quibria reiterated a Buy rating on ADC Therapeutics today and set a price target of $10.00. The company’s shares closed last Thursday at $4.60.
According to TipRanks.com, Quibria has 0 stars on 0-5 stars ranking scale with an average return of
ADC Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $10.20, which is an 113.8% upside from current levels. In a report issued on March 28, Guggenheim also initiated coverage with a Buy rating on the stock with a $11.00 price target.
See the top stocks recommended by analysts >>
Adial Pharmaceuticals (ADIL)
Maxim Group analyst Jason McCarthy maintained a Hold rating on Adial Pharmaceuticals yesterday. The company’s shares closed last Thursday at $2.61, close to its 52-week low of $0.77.
According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Adial Pharmaceuticals is a Moderate Buy with an average price target of $26.00.
Steris (STE)
In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Steris, with a price target of $265.00. The company’s shares closed last Thursday at $207.58.
According to TipRanks.com, Turkaly is a 1-star analyst with an average return of
Steris has an analyst consensus of Moderate Buy, with a price target consensus of $197.27, a -6.5% downside from current levels. In a report issued on April 4, Wolfe Research also maintained a Buy rating on the stock with a $245.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ADCT:
- ADC Therapeutics Showcases Cancer Treatment Innovations
- ADC Therapeutics completes dose escalation in LOTIS-7 to treat r/r B-NHL
- ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
- ADC Therapeutics initiated with a Buy at Guggenheim
